A股異動 | 實控人擬發生變更 海王生物高開低走 現跌超7%
深圳知名醫藥流通上市公司海王生物(000078.SZ)高開低走,現跌超7%報2.36元,總市值65億元。該股此前曾持續拉昇上升,或因利好落地股價回調。消息上,公司控股股東海王集團擬將其持有的31573.48萬股股份協議轉讓給絲紡集團,佔公司股份總數的11.48%。同時,海王集團及其一致行動人將放棄其持有的90071.03萬股股份的表決權。交易完成後,絲紡集團將成為公司控股股東,實際控制人變更為廣東省人民政府。此外,公司擬向特定對象發行不超過6.2億股新股,絲紡集團及其控股股東廣新集團將全額認購。交易尚需廣東省國資委批覆、市場監督管理總局審查及深交所合規確認。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.